251 related articles for article (PubMed ID: 22270933)
1. Stromal-epithelial interactions modulate cross-talk between prolactin receptor and HER2/Neu in breast cancer.
Xu C; Langenheim JF; Chen WY
Breast Cancer Res Treat; 2012 Jul; 134(1):157-69. PubMed ID: 22270933
[TBL] [Abstract][Full Text] [Related]
2. Additive effects of a prolactin receptor antagonist, G129R, and herceptin on inhibition of HER2-overexpressing breast cancer cells.
Scotti ML; Langenheim JF; Tomblyn S; Springs AE; Chen WY
Breast Cancer Res Treat; 2008 Sep; 111(2):241-50. PubMed ID: 17955362
[TBL] [Abstract][Full Text] [Related]
3. Prolactin antagonist-endostatin fusion protein as a targeted dual-functional therapeutic agent for breast cancer.
Beck MT; Chen NY; Franek KJ; Chen WY
Cancer Res; 2003 Jul; 63(13):3598-604. PubMed ID: 12839947
[TBL] [Abstract][Full Text] [Related]
4. Combination therapy using three novel prolactin receptor antagonist-based fusion proteins effectively inhibits tumor recurrence and metastasis in HER2/neu transgenic mice.
Tomblyn S; Springs AE; Langenheim JF; Chen WY
Int J Oncol; 2009 Apr; 34(4):1139-46. PubMed ID: 19287973
[TBL] [Abstract][Full Text] [Related]
5. A human prolactin antagonist, hPRL-G129R, inhibits breast cancer cell proliferation through induction of apoptosis.
Chen WY; Ramamoorthy P; Chen N; Sticca R; Wagner TE
Clin Cancer Res; 1999 Nov; 5(11):3583-93. PubMed ID: 10589775
[TBL] [Abstract][Full Text] [Related]
6. p130Cas as a new regulator of mammary epithelial cell proliferation, survival, and HER2-neu oncogene-dependent breast tumorigenesis.
Cabodi S; Tinnirello A; Di Stefano P; Bisarò B; Ambrosino E; Castellano I; Sapino A; Arisio R; Cavallo F; Forni G; Glukhova M; Silengo L; Altruda F; Turco E; Tarone G; Defilippi P
Cancer Res; 2006 May; 66(9):4672-80. PubMed ID: 16651418
[TBL] [Abstract][Full Text] [Related]
7. The role of human prolactin and its antagonist, G129R, in mammary gland development and DMBA-initiated tumorigenesis in transgenic mice.
Tomblyn S; Langenheim JF; Jacquemart IC; Holle E; Chen WY
Int J Oncol; 2005 Nov; 27(5):1381-9. PubMed ID: 16211235
[TBL] [Abstract][Full Text] [Related]
8. Development of a prolactin receptor-targeting fusion toxin using a prolactin antagonist and a recombinant form of Pseudomonas exotoxin A.
Langenheim JF; Chen WY
Breast Cancer Res Treat; 2005 Apr; 90(3):281-93. PubMed ID: 15830142
[TBL] [Abstract][Full Text] [Related]
9. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
Moulder SL; Yakes FM; Muthuswamy SK; Bianco R; Simpson JF; Arteaga CL
Cancer Res; 2001 Dec; 61(24):8887-95. PubMed ID: 11751413
[TBL] [Abstract][Full Text] [Related]
10. A Novel Mechanism of hPRL-G129R, a Prolactin Antagonist, Inhibits Human Breast Cancer Cell Proliferation and Migration.
Li R; Yang Y; Lan H; Wang Y; Ge Z; Liu X; Zhou Y; Zhang W; Xian L; Yuan H
Endocrinology; 2023 Nov; 164(12):. PubMed ID: 37934803
[TBL] [Abstract][Full Text] [Related]
11. Epithelial and fibroblast cell lines derived from a spontaneous mammary carcinoma in a MMTV/neu transgenic mouse.
Campbell MJ; Wollish WS; Lobo M; Esserman LJ
In Vitro Cell Dev Biol Anim; 2002 Jun; 38(6):326-33. PubMed ID: 12513120
[TBL] [Abstract][Full Text] [Related]
12. Curcumin induces apoptosis in breast cancer cell lines and delays the growth of mammary tumors in neu transgenic mice.
Masuelli L; Benvenuto M; Fantini M; Marzocchella L; Sacchetti P; Di Stefano E; Tresoldi I; Izzi V; Bernardini R; Palumbo C; Mattei M; Lista F; Galvano F; Modesti A; Bei R
J Biol Regul Homeost Agents; 2013; 27(1):105-19. PubMed ID: 23489691
[TBL] [Abstract][Full Text] [Related]
13. Functional interaction between mouse erbB3 and wild-type rat c-neu in transgenic mouse mammary tumor cells.
Kim A; Liu B; Ordonez-Ercan D; Alvarez KM; Jones LD; McKimmey C; Edgerton SM; Yang X; Thor AD
Breast Cancer Res; 2005; 7(5):R708-18. PubMed ID: 16168116
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of oncogene STAT3 phosphorylation by a prolactin antagonist, hPRL-G129R, in T-47D human breast cancer cells.
Cataldo L; Chen NY; Yuan Q; Li W; Ramamoorthy P; Wagner TE; Sticca RP; Chen WY
Int J Oncol; 2000 Dec; 17(6):1179-85. PubMed ID: 11078803
[TBL] [Abstract][Full Text] [Related]
15. CD49f and CD61 identify Her2/neu-induced mammary tumor-initiating cells that are potentially derived from luminal progenitors and maintained by the integrin-TGFβ signaling.
Lo PK; Kanojia D; Liu X; Singh UP; Berger FG; Wang Q; Chen H
Oncogene; 2012 May; 31(21):2614-26. PubMed ID: 21996747
[TBL] [Abstract][Full Text] [Related]
16. Prolactin drives estrogen receptor-alpha-dependent ductal expansion and synergizes with transforming growth factor-alpha to induce mammary tumors in males.
Arendt LM; Schuler LA
Am J Pathol; 2008 Jan; 172(1):194-202. PubMed ID: 18156207
[TBL] [Abstract][Full Text] [Related]
17. Prolactin modulates phosphorylation, signaling and trafficking of epidermal growth factor receptor in human T47D breast cancer cells.
Huang Y; Li X; Jiang J; Frank SJ
Oncogene; 2006 Dec; 25(58):7565-76. PubMed ID: 16785991
[TBL] [Abstract][Full Text] [Related]
18. In vivo studies of the anti-tumor effects of a human prolactin antagonist, hPRL-G129R.
Chen NY; Holle L; Li W; Peirce SK; Beck MT; Chen WY
Int J Oncol; 2002 Apr; 20(4):813-8. PubMed ID: 11894130
[TBL] [Abstract][Full Text] [Related]
19. Hormone-sensing cells require Wip1 for paracrine stimulation in normal and premalignant mammary epithelium.
Tarulli GA; De Silva D; Ho V; Kunasegaran K; Ghosh K; Tan BC; Bulavin DV; Pietersen AM
Breast Cancer Res; 2013 Jan; 15(1):R10. PubMed ID: 23369183
[TBL] [Abstract][Full Text] [Related]
20. A novel design of targeted endocrine and cytokine therapy for breast cancer.
Zhang G; Li W; Holle L; Chen N; Chen WY
Clin Cancer Res; 2002 Apr; 8(4):1196-205. PubMed ID: 11948133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
